- Title: Altered visual evoked potentials associated with verbal and nonverbal skills in Fragile X
 syndrome.
- **Authors:** Elizabeth Saoud^{1,2*}, John Fitzgerald³, Megan Hartney², and Carol L. Wilkinson²
- 6 Affiliations:
- 7 ¹Department of Neuroscience, Harvard University, Boston, MA 02138, USA
- ²Division of Developmental Medicine, Boston Children's Hospital, Harvard Medical School,
 Boston, MA 02115, USA.
- 10 ³Department of Psychology and Brain Sciences, Dartmouth College, Hanover, NH 03755 USA
- 12 *To whom correspondence should be addressed: Carol Wilkinson
- 13 Labs of Cognitive Neuroscience
- 14 2 Brookline Place, Brookline, MA 02445
- 15 <u>Carol.Wilkinson@childrens.harvard.edu</u>
- 17 Short Title: VEP measures associated with verbal and nonverbal development in FXS
- **Key Words:** EEG, VEP, Event Related Potential, Language Development, Child Development

1 Abstract

2

Background: Understanding the neurobiology behind Fragile X syndrome (FXS) is critical in
 identifying effective therapeutics and improving care for affected individuals.

5 Electroencephalography (EEG) provides an opportunity to investigate the biological foundations

6 of this disorder. We aimed to characterize the visual evoked potential (VEP) in young children

7 with FXS, and to understand how measures of the VEP are associated with verbal and

- 8 nonverbal development within FXS.
- 9 Methods: VEPs were collected in children between 2-7 years old with FXS (n = 9) as well as

10 corresponding age- (n = 10) and cognitive-matched (n = 9) typically developing children.

11 Additionally, the Mullen Scales of Early Learning and Preschool Language Scales were

12 administered to collect measures of verbal and nonverbal development. Differences in

13 component amplitudes and latencies of the VEP were assessed using ANCOVAs, and

14 associations of VEP measures and verbal and nonverbal development were evaluated using

15 linear regression with age as a covariate.

16 **Results:** No differences between groups were observed in N1, P1, or N2 VEP components.

17 However, a consistent and prominent P2 component (latency = 177ms ± 13.7), was observed in

18 children with FXS. The P2 amplitude was significantly increased in FXS children compared to

19 the cognitive-matched group (p = 0.004). For children with FXS, the amplitude of several VEP

20 components were associated with verbal and nonverbal development; larger N1 amplitude and

smaller P1 and P2 amplitudes were all associated with better receptive language (all p<0.05)

22 and larger N1 amplitude was also associated with better fine motor skills (p<0.05).

Conclusions: The observed increase in P2 amplitude and its negative association with
 language development within the FXS group supports the P2 component as a potential
 biomarker for FXS as a disorder, as well as a pathophysiological marker of verbal impairment
 that could be used in clinical trials.

27 28

29

30 31

0 21

- 32
- 33
- 34 35

1 Background

2 Fragile X Syndrome (FXS) is the most common inherited form of intellectual disability. 3 and children with FXS often struggle with severe language impairments as well as sensory and 4 behavioral challenges (Hagerman et al., 2017). FXS is caused by a CGG trinucleotide repeat expansion on the X chromosome, leading to silencing of the Fmr1 gene. This reduces 5 6 production of Fragile X Messenger Ribonucleoprotein 1 (FMRP), leading to overexpression of 7 other local proteins that negatively impact synapse development, strength, and plasticity 8 (Garber et al., 2008). The cognitive and behavioral deficits experienced by children with FXS overlap with other neurodevelopmental disorders. For example, around 50% of males with FXS 9 10 meet criteria for autism spectrum disorder (CDC, 2021), and many if not the majority of children 11 with FXS meet criteria for attention deficit hyperactivity disorder (ADHD) and anxiety (Hagerman 12 et al., 2009). The neuropathology underlying FXS points to an imbalance of neural excitation 13 and inhibition (Contractor et al., 2015), which likely disrupts downstream synaptic and homeostatic plasticity and ultimately learning and memory. Mouse models of FXS exhibit 14 reduced GABA transmission, resulting in over-excitation (Gibson et al., 2008; Lozano et al., 15 16 2014), and several GABA agonists have successfully improved physiological and behavioral phenotypes in mice (Henderson et al., 2012; Qin et al., 2015). Unfortunately, most human phase 17 18 Il trials have not been successful in part due to the lack of validated brain-based biomarkers to monitor clinical improvement (Berry-Kravis et al., 2013; Jacquemont et al., 2014). 19

20 The visual evoked potential (VEP) has potential as a brain-based biomarker candidate in 21 neurodevelopmental disorders as it has been used in both human and mouse studies, and is non-invasive, low cost, and feasibly collected across the lifespan from infants to adults. As a 22 neural measure, the VEP provides information both about integrity of the visual pathway and 23 24 higher-level cognitive processing of sensory information. As such, the VEP can be used as a 25 neurological biomarker, inform underlying neurophysiology, and map progression of disorders 26 that affect sensory systems (Odom et al., 2004). Several studies have examined differences in 27 VEP across several neurodevelopmental disorders, including FXS, Down syndrome, 16p11.2 28 variants, tuberous sclerosis complex (TSC), and Rett syndrome. Alterations in component 29 amplitudes have been observed across disorders, with increased P1 amplitude in 16p11.2 30 deletions (LeBlanc & Nelson, 2016) and TSC (Varcin et al., 2016), and decreased P1 amplitude 31 in 16p11.2 duplications (LeBlanc & Nelson, 2016) and Rett syndrome (LeBlanc et al., 2015). In 32 FXS, a study of VEP response in individuals 10-22 years old observed increased N1 and N2 33 amplitude when compared to age-matched, but not cognitive matched comparison groups

(Knoth et al., 2014). Despite differences being observed in a range of neurodevelopmental
disorders, few studies have examined the relationship between VEP responses and behavioral
and cognitive outcomes – a crucial component of biomarker identification. Further in FXS, there
have been few EEG studies in young children; identification of EEG based biomarkers
associated with developmental outcomes at these young ages is crucial to biomarker efficacy in
clinical trials for young children.

This study had two main aims. First, we characterize the VEP in children with FXS
compared to both age- and cognitive-matched comparison groups. We hypothesized that FXS
children would have differences in their VEP components compared to both groups. Second,
within the FXS group we assess how VEP measures are associated with varying levels of
cognitive and language development.

12

13 Methods

14

15 **Participants**

Table 1 describes participant characteristics. A total of 16 FXS children (age 33-78 months old) with full mutation of *Fmr1* and 12 similarly aged typically developing children were recruited for this study (IRB#P00025493) conducted at the Labs of Cognitive Neuroscience at Boston Children's Hospital. 6 FXS participants and 1 age-matched participant did not complete VEP EEG acquisition. VEP data from 1 FXS and 1 age-matched participant was excluded due to excessive artifact. VEP and behavioral data was analyzed for a total of 9 FXS participants and 10 age-control participants.

23

24 FXS and age-controls: FXS participants all had documented full mutation of the Fmr1 25 gene; however, methylation status was not known for all participants. All data was collected prior to the COVID pandemic, which halted additional recruitment. Prior to this, 1 female 26 27 participant with FXS had been enrolled, but we had not yet enrolled an age- and sex-matched comparison participant. Therefore, the age- matched comparison groups were composed of all 28 29 males. Across FXS and age-matched groups, additional exclusion criteria included history of 30 prematurity (< 35 weeks gestational age), low birth weight (< 2000 g), known birth trauma, 31 known genetic disorders, unstable seizure disorder, current use of anticonvulsant medication, 32 and uncorrected hearing or vision problems. Children were required to be from a primarily 33 English-speaking household with English spoken more than 50% of the time.

1

2 Table 1: Demographics of Subjects

	Age- Matched (N = 10)	FXS (N = 9)	Cognitive- Matched (N = 9)
Age, mean in months (SD)	48.6 (14.1)	44.3 (14.5)	25.2 (8.5)
Highest parental education, n (%)			
≤ High school/GED	0 (0)	0 (0)	0 (0)
Associate's degree	0 (0)	1 (11)	0 (0)
Bachelor's degree	1 (10)	2 (22)	1 (11)
Graduate or professional degree(s)	9 (90)	6 (67)	8 (89)
Household income, n (%)			
< \$40,000	0 (0)	0 (0)	0 (0)
\$40-70,000	0 (0)	3 (33)	1 (11)
>\$70,000	10 (100)	6 (67)	8 (89)
No response	0 (0)	0 (0)	0 (0)
Sex, n (%)			
Female	0 (0)	1 (11)	3 (33)
Male	10 (100)	8 (89)	6 (67)
Race, n (%)			
White	6 (60)	6 (67)	6 (67)
Black/African American	0 (0)	0 (0)	0 (0)
Asian	0 (0)	1 (11)	0 (0)
Multi_race	4 (40)	1 (11)	3 (33)
No response	0 (0)	1 (11)	0 (0)
Ethnicity, n (%)			
Hispanic or Latino	0 (0)	2 (22)	2 (22)
Mullen Scales of Early Learning (mean ± SD)			
Nonverbal Developmental Quotient	109.1 ± 11.0	59.1 ± 13.6	110.1 ± 17.8
Visual Reception Raw Score	44.8 ± 3.4	28.4 ± 7.2	28.0 ± 5.5
Fine Motor Raw Score	38.0 ± 4.5	24.4 ± 4.2	25.6 ± 5.3
EEG Quality Measures (mean ± SD)			
Number of Trials Post Rejection	91.3 ± 9.8	76.4 ± 20.1	91.2 ± 11.1
Percent Good Channels	91.5 ± 9.6 80.6 ± 10.8	70.4 ± 20.1 80.9 ± 6.1	91.2 ± 11.1 87.7 ± 7.8
1 Hz Pre and Post Wav-Thresholding	0.72 ± 0.17	0.9 ± 0.1 0.66 ± 0.15	07.7 ± 7.0 0.86 ± 0.05
Correlation	U.12 I U.11	0.00 ± 0.13	0.00 ± 0.00

Cognitive matched controls: VEP data from an additional 9 cognitive-matched children were analyzed. Individuals from this group provided data as part of a concurrent longitudinal study (IRB#P00018377) in infants 12-36 months old which used the same VEP paradigm in the same EEG rooms. Exclusion criteria were the same as above. Participants were matched based on raw Fine Motor and Visual Reception scores on the Mullen Scales of Early Learning (see Methods: Developmental Assessment).

Institutional review board approval was obtained prior to starting the study, and written,
informed consent was obtained from all parents or guardians prior to their child's participation.

9

10 Developmental Assessment

Nonverbal subscales (Fine Motor and Visual Reception) of the Mullen Scales of Early
Learning (MSEL; Mullen, 1995) were administered to all FXS and cognitive-matched
participants, and age-matched controls under 70 months of age. The Preschool Language Scale
5th Edition (PLS; Zimmerman et al., 2011) was administered to FXS and age-matched controls.
The PLS assesses early language development, including both receptive and expressive
language skills. We utilized the raw scores from the Expressive Communication and Auditory
Comprehension subscales.

18

19 VEP collection

20 EEG data were collected in a dimly lit, sound-attenuated, electrically shielded room. The 21 child sat either in their caregiver's lap or independently in a chair or stroller while looking at a Tobii 120 monitor (Tobii Technology, Sweden) approximately 60cm away, and caregivers were 22 instructed to avoid social interactions with their child. A research assistant was also present in 23 24 the room to help keep the child calm and focused, if necessary. Pattern-reversal visual stimuli, 25 consisting of a reversing black and white checkerboard pattern (with diagonal check size of 0.5cpd), were presented on the monitor using ePrime software (Psychology Software Tools Inc., 26 27 Pittsburgh, PA, USA). Stimuli were presented for at least 500ms as the stimulus phase-reversal was contingent on binocular fixation on the monitor for a period of 100ms to ensure the 28 29 participant was looking for each trial. In a small number of cases, the eye tracking software did 30 not accurately pick up on the child's binocular fixation. In these cases, the research assistant 31 manual progressed the stimuli based on whether the child was looking at the screen. A 32 maximum of 200 trials were presented, with fewer trials presented if the child became 33 inattentive. Continuous EEG was recorded using a 128-channel high density HydroCel

Geodesic Sensor Net and amplified with a NetAmps 300 high-input amplifier (Electrical
Geodesics Inc., Eugene, OR, USA). Data were sampled at 1000Hz, and impedance was kept
below 100kOhms in accordance with the impedance capabilities of the high-impedance
amplifiers inside the electrically shielded room (Ferree et al., 2001).

5

6 EEG pre-processing

7 Raw Netstation files were pre-processed, and artifact was removed using the Harvard 8 Automated Processing Pipeline for EEG plus Event-Related Software (HAPPE+ER; Monachino et al., 2021). Line noise was removed using Cleanline's multi-taper regression, data was low 9 10 pass filtered at 100Hz, and bad channels were removed. Artifact was then extracted using 11 wavelet-thresholding with wavelet resolution level set to ≤0.1Hz as determined to be optimal in 12 infant VEP analyses by Monachino et al. 2021. Data was then filtered (0.3-30Hz) and 13 segmented (-100 to 400ms) around the visual stimulus, and baseline corrected via mean subtraction. Segments with retained artifact in the region of interest used for VEP analysis 14 (Electrodes: O1, O2, 71, 75, and 76) were then rejected using HAPPE+ER's amplitude and joint 15 16 probability method with an artifact threshold of +200 µV. Bad channels were then interpolated and data was referenced to the average reference. 17

18

19 EEG rejection criteria

EEGs were excluded from the final sample if (1) they had fewer than 20 trials post segment rejection, (2) >3/5 electrodes in the region of interest were interpolated, or (3) they did not meet the following HAPPE+ER quality metrics: cross-correlation value < 0.2 for pre/post wavelet thresholding for frequencies 0.5, 1, and 2Hz. 1 FXS and 1 age-matched participant were excluded based on the above criteria.

25

26 VEP analysis

Grand average waveforms were calculated by averaging the 5 occipital electrodes described above. Given observed differences in latency of components between groups, components were identified as follows: The P1 component was identified as the most positive peak between 80-120ms after stimulus onset. The N1 and N2 components were then identified as the relative minimums that come before and after the P1, respectively. The P2 component was identified as the relative maximum after the N2. Finally, N1-P1 amplitude was calculated as the amplitude of the P1 measured from the preceding N1 peak, and P1-N2 amplitude was

calculated as the amplitude of the N2 measured from the preceding P1 peak. Individual VEPs
were visually inspected to confirm or adjust VEP components.

3

4 Statistical analysis

5 ANCOVAs with post-hoc pairwise Tukey HDR tests were conducted to determine if there 6 were significant differences in the mean VEP amplitude and latencies between groups, while 7 accounting for covariates related to data quality, specifically number of trials post-rejection and 8 1Hz pre- and post-thresholding correlation. A false discovery rate (FDR) correction was used to 9 account for the multiple comparisons made for each analysis.

- Linear regression was used to determine if component amplitudes were associated with nonverbal and language measures within the FXS group. Raw scores were used, and age was included as a covariate, as both VEP and raw scores on behavioral tests change with age. Analyses were performed in Python 3.9 with Statsmodels and Pingouin. Figures were created
- 14 using python data visualization libraries [matplotlib (Hunter, 2007) and Seaborn
- 15 (https://seaborn.pydata.org/index.html)]
- 16

17 Results

18

19 Sample Description

20 A summary of the demographic information and mean scores for MSEL nonverbal scales 21 are shown in Table 1. As expected, the mean nonverbal developmental quotient (NVDQ) was lower for the FXS group, reflecting developmental delays associated with this syndrome. Raw 22 scores on subscales were well matched between FXS and cognitive-matched controls. EEG 23 24 guality measures are also shown in Table 1. The FXS group had a significantly smaller number 25 of trials post-rejection (ANOVA, p = 0.048) and a significantly smaller 1Hz pre- and postthresholding correlation (ANOVA, p = 0.004) when compared to its control groups. This latter 26 27 value suggests that EEG data collected from the FXS group, had greater signal change before 28 and after wavelet thresholding likely due to increased noise in the data, although mean values 29 across all measures were well above our exclusion criteria. Given the significant differences 30 between groups, EEG quality measures were used as co-variates in statistical analyses.

31

32 VEP Waveform

1 Grand-averaged VEPs for the FXS, age-matched, and cognitive-matched groups are

2 shown in Figure 1. All groups demonstrated a typical N1-P1-N2 pattern response. However, a

3 prominent P2 was also observed in the FXS group. Statistical analyses (Table 2) confirmed a

4 Table 2: Summary of Amplitude and Latencies of Components

	Age- Matched, mean ± SD	FXS , mean ± SD	Cognitive- Matched , mean ± SD	ANCOVA , F	<i>P</i> Value, unadjusted; adjusted	
Component Amplitude (µV)						
N1 Amplitude	-4.56 ± 3.48	-6.77 ± 6.00	-6.24 ± 4.16	1.518	0.240; 0.321	
P1 Amplitude	3.63 ± 4.29	6.71 ± 6.97	3.13 ± 4.05	1.128	0.341; 0.379	
N2 Amplitude	-2.32 ± 5.04	0.80 ± 8.42	-7.97 ± 6.09	2.496	0.105; 0.261	
P2 Amplitude	0.95 ± 5.39	8.63 ± 5.62	-1.48 ± 5.14	6.769	0.005; 0.049	
N1P1 Amplitude	8.19 ± 5.04	13.5 ± 7.26	9.37 ± 6.01	2.648	0.092; 0.261	
P1N2 Amplitude	5.95 ± 4.50	5.91 ± 3.64	11.1 ± 6.81	1.630	0.218; 0.321	
Latency (ms)						
N1 Latency	56.6 ± 9.29	64.2 ± 4.94	63.8 ± 9.46	2.789	0.082; 0.261	
P1 Latency	93.4 ± 4.43	97.1 ± 8.95	96.0 ± 6.08	0.445	0.646; 0.646	
N2 Latency	126 ± 13.6	127 ± 11.5	138 ± 14.2	1.499	0.245; 0.321	
P2 Latency	160 ± 20.0	177 ± 13.7	182 ± 27.3	1.442	0.257; 0.321	

5

significant group effect for P2 amplitude, and post-hoc pairwise Tukey HSD tests demonstrated
FXS children having significantly increased P2 amplitude compared to the cognitive-matched (p
= 0.004, Figure 1) comparison group. A similar trend was observed when compared to the agematched comparison group, but with marginal significance (p = 0.052). While there was no
significant difference in P2 latency, we observed more consistent timing of the P2 within the
FXS group (Coefficient of variance FXS = 0.07, Age-Matched = 0.12; Cog-Matched = 0.14;
Figure 1). No other components showed significant differences between groups.




Figure 1: (A) Grand-averaged VEPs are shown, with 95% confidence intervals. (B) Mean P2 Amplitude across trials across groups. P values shown are in comparison to the FXS group.


2 3

1

4 VEP and Nonverbal Development

We next examined whether component amplitudes were associated with measures of
nonverbal development, specifically the MSEL visual reception and fine motor subscales.
Results from linear regression analyses with age included as a covariate are shown in Table 3.
Within the FXS group, a larger, more negative N1 was correlated with higher fine motor scores.
All other associations were not significant. Visualization of unadjusted Pearson correlation

10 between N1 and fine motor scores is shown in Figure 2.



10 measured using the PLS-5. Linear regressions with age as a covariate found that larger N1

0 P1 A


40

20

-15

FXS

- 120 amplitude, and smaller P1 and P2 amplitudes were associated with better receptive language 1 skills (p = 0.028, p = 0.017, p = 0.020, respectively; Table 3). Additionally, association betwee 100 2 the N2 amplitude and Auditory Comprehension raw score was marginally significant (p = 0.05) 80 3 Total Langu Only marginally significant associations were found between component amplitudes and the 4 60
- Expressive Communication subscale. Visualization of unadjusted Pearson correlations are 5
- 6 shown in Figure 3. Note that the PLS-5 was only administered to FXS and age-matched
- 7 controls.



significant trend when compared to the age-matched group. Prior ERP studies in male adults 1 2 with FXS have observed increased P2 amplitude in response to auditory but not in response to visual stimuli (Knoth & Lippé, 2012; Van der Molen et al., 2012). In another study specifically 3 4 using a checkboard VEP stimulus, Knoth et al. also did not observe differences in P2 amplitude. However, this study was in an older population (10-22 years) that included a larger percentage 5 6 of females who, although had full mutation, were also mosaic, which is associated with less 7 severe symptom presentation (Knoth et al., 2014). The VEP P2 component has been less well 8 studied than early components, but is thought to represent both primary sensory and higher cognitive processing. It has been suggested that P2 amplitude is negatively associated with 9 10 attention. However, as our task was passive, we do not have a simultaneous measure of 11 attention to determine whether decreased attention was associated with increased P2 amplitude 12 in this sample. There is some evidence that P2 response in a visual priming task in adults is 13 associated with theta (4-6Hz) phase-locking (Freunberger et al., 2007), and interestingly, 14 studies in FXS adults have observed increased theta power in response to auditory stimuli compared to age-matched adults without FXS (Ethridge et al., 2019). 15

16

Differences in VEP component amplitudes have also been observed in several genetic 17 18 neurodevelopmental disorders including tuberous sclerosis complex and 16p11.2 copy number variants (LeBlanc & Nelson, 2016; Varcin et al., 2016). Most of these studies identify differences 19 20 in the early components, namely the N1 and P1, which are hypothesized to be related to early 21 processing of sensory information. In our FXS participants we observed only a marginally significant group effect for the N1-P1 amplitude prior to adjusting for multiple comparisons, with 22 the FXS group having a larger N1-P1 amplitude compared to comparison groups. The P2 23 24 component has not been extensively studied in other neurodevelopmental disorders. However, 25 we do note that VEP waveforms obtained in Rett syndrome patients visually appear to have an increased P2 amplitude, although this relationship was not statistically assessed (LeBlanc et al., 26 27 2015). Identifying genetic disorders with shared ERP findings could shed further light on the 28 underlying mechanisms of the altered P2 component.

- 29 30

31 VEP Associations with Nonverbal and Verbal Measures

Previous studies have examined correlations between VEP component amplitudes and
 various measures of development, finding that increases in component amplitudes are often

associated with better outcomes in typically developing populations (Jensen et al., 2019; 1 2 Josiassen et al., 1988). We hypothesized that N1 and P1 amplitudes would be associated with nonverbal developmental measures. Indeed, we observed that within the FXS group a larger 3 4 (more negative) N1 amplitude was associated with better fine motor skills after adjusting for age. Significant associations between other components and non-verbal measures were not 5 6 observed. In addition, we did not observe significant associations between VEP components 7 and nonverbal development within the two typically developing samples, although our sample 8 size is small, so negative findings must be interpreted with caution.

9 We also examined associations between component amplitudes and measures of verbal 10 development. Here, a larger (more negative) N1 amplitude and smaller (less positive) P1 and 11 P2 amplitudes were significantly associated with better receptive language within the FXS 12 group. Association between N2 amplitude and receptive language was marginally significant. 13 Associations between VEP measures and expressive communication were not found to be 14 significant, although the trends were consistent across these measures for FXS children. Our finding that both early (N1) and later (P2) components are associated with receptive language, 15 could be interpreted in several ways. First, it may suggest that alterations in visual sensory 16 17 processing affect language development, with receptive language processing being more 18 affected due to its increased reliance on additional visual information, especially at young ages. Alternatively, these findings may instead reflect global network alterations within FXS, such as 19 20 imbalances in glutamatergic/GABAergic signaling, separately affecting visual brain responses 21 and language development. In this same cohort of subjects, we found that increased aperiodic gamma power, hypothesized to be a marker increased cortical excitation, was associated with 22 23 better language abilities (Wilkinson & Nelson, 2021). Differences in basal neuronal network 24 excitability could cause differences in VEP response. Exploratory correlation analysis between 25 baseline aperiodic gamma power VEP components found no significant associations, however given the small sample size, further analysis in larger populations is necessary to determine the 26 27 relationships between underlying network activity and brain responses to stimuli.

28

Finally, a larger (more negative) N1 amplitude was associated with both better verbal and nonverbal measures, suggesting it may be a proxy of overall cognitive functioning. Ethridge et al. 2019 similarly observed that a larger N1 amplitude in response to an auditory habituation task, was associated with better scores on Woodcock-Johnson III Test of Cognitive Abilities Auditory Attention subscale. Authors hypothesized that the increased N1 amplitude within the

- FXS population may reflect increased hyper-vigilance and in turn improved ability to complete
 standardized tests.
- 3

4 Limitations and Clinical Relevance

FXS is a rare genetic disorder, which creates challenges in recruiting large patient 5 6 samples. In addition, collecting high quality EEG data is challenging in young populations with limited communication abilities and increased behavioral challenges. Despite the small sample 7 8 size, our findings present a promising future avenue for clinical use. Namely, the VEP P2 9 component is worthy of continued study as a potential biomarker for FXS itself, as the P2 10 amplitude was significantly increased in FXS children and often weak or absent in typically developing populations. In addition, this paper contributes to a field of research that is beginning 11 12 to reveal VEP N1 and P2 amplitudes as a useful neurobiological outcome measure of

13 developmental levels that could be used in clinical trials.

1415 **Bibliography**

16

Berry-Kravis, E., Hessl, D., Abbeduto, L., Reiss, A. L., Beckel-Mitchener, A., & Urv, T. K. (2013).
 Outcome Measures for Clinical Trials in Fragile X Syndrome. *Journal of Developmental & Behavioral Pediatrics*, *34*(7), 508–522. https://doi.org/10.1097/DBP.0b013e31829d1f20

Contractor, A., Klyachko, V. A., & Portera-Cailliau, C. (2015). Altered Neuronal and Circuit
 Excitability in Fragile X Syndrome. *Neuron*, 87(4), 699–715.

22 https://doi.org/10.1016/j.neuron.2015.06.017

- Ethridge, L. E., de Stefano, L. A., Schmitt, L. M., Woodruff, N. E., Brown, K. L., Tran, M., Wang,
 J., Pedapati, E. v., Erickson, C. A., & Sweeney, J. A. (2019). Auditory EEG Biomarkers in
 Fragile X Syndrome: Clinical Relevance. *Frontiers in Integrative Neuroscience*, *13*.
 https://doi.org/10.3389/fnint.2019.00060
- Ferree, T. C., Luu, P., Russell, G. S., & Tucker, D. M. (2001). Scalp electrode impedance,
 infection risk, and EEG data quality. *Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology*, *112*(3), 536–544.
 https://doi.org/10.1016/s1388-2457(00)00533-2
- Freunberger, R., Klimesch, W., Doppelmayr, M., & Höller, Y. (2007). Visual P2 component is
 related to theta phase-locking. *Neuroscience Letters*, *426*(3), 181–186.
 https://doi.org/10.1016/j.neulet.2007.08.062
- Garber, K. B., Visootsak, J., & Warren, S. T. (2008). Fragile X syndrome. *European Journal of Human Genetics*, *16*(6), 666–672. https://doi.org/10.1038/ejhg.2008.61
- Gibson, J. R., Bartley, A. F., Hays, S. A., & Huber, K. M. (2008). Imbalance of Neocortical
 Excitation and Inhibition and Altered UP States Reflect Network Hyperexcitability in the
 Mouse Model of Fragile X Syndrome. *Journal of Neurophysiology*, *100*(5), 2615–2626.
- 39 https://doi.org/10.1152/jn.90752.2008

Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, 1 2 F., Gantois, I., Sonenberg, N., Mandel, J. L., & Hagerman, P. J. (2017). Fragile X 3 syndrome. Nature Reviews Disease Primers, 3(1), 17065. 4 https://doi.org/10.1038/nrdp.2017.65 5 Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., Picker, J., Gane, L., & Tranfaglia, M. 6 7 (2009). Advances in the Treatment of Fragile X Syndrome. Pediatrics, 123(1), 378-390. 8 https://doi.org/10.1542/peds.2008-0317 Henderson, C., Wijetunge, L., Kinoshita, M. N., Shumway, M., Hammond, R. S., Postma, F. R., 9 Brynczka, C., Rush, R., Thomas, A., Paylor, R., Warren, S. T., Vanderklish, P. W., Kind, P. 10 C., Carpenter, R. L., Bear, M. F., & Healy, A. M. (2012). Reversal of Disease-Related 11 Pathologies in the Fragile X Mouse Model by Selective Activation of GABA B Receptors with 12 13 Arbaclofen. Science Translational Medicine, 4(152), 152ra128. https://doi.org/10.1126/scitransImed.3004218 14 15 Hunter, J. D. (2007). Matplotlib: A 2D Graphics Environment. Computing in Science & Engineering, 9(3), 90-95. https://doi.org/10.1109/MCSE.2007.55 16 17 Jacquemont, S., Berry-Kravis, E., Hagerman, R., von Raison, F., Gasparini, F., Apostol, G., Ufer, M., des Portes, V., & Gomez-Mancilla, B. (2014). The challenges of clinical trials in 18 fragile X syndrome. Psychopharmacology, 231(6), 1237-1250. 19 https://doi.org/10.1007/s00213-013-3289-0 20 Jensen, S. K. G., Kumar, S., Xie, W., Tofail, F., Haque, R., Petri, W. A., & Nelson, C. A. (2019). 21 Neural correlates of early adversity among Bangladeshi infants. Scientific Reports, 9(1), 22 3507. https://doi.org/10.1038/s41598-019-39242-x 23 Josiassen, R. C., Shagass, C., Roemer, R. A., & Slepner, S. (1988). Evoked potential correlates 24 25 of intelligence in nonpatient subjects. Biological Psychology, 27(3), 207-225. https://doi.org/10.1016/0301-0511(88)90031-2 26 Knoth, I. S., & Lippé, S. (2012). Event-related potential alterations in fragile X syndrome. 27 Frontiers in Human Neuroscience, 6, 264. https://doi.org/10.3389/fnhum.2012.00264 28 Knoth, I. S., Vannasing, P., Major, P., Michaud, J. L., & Lippé, S. (2014). Alterations of visual 29 30 and auditory evoked potentials in fragile X syndrome. International Journal of Developmental Neuroscience, 36, 90–97. https://doi.org/10.1016/j.ijdevneu.2014.05.003 31 32 LeBlanc, J. J., DeGregorio, G., Centofante, E., Vogel-Farley, V. K., Barnes, K., Kaufmann, W. E., Fagiolini, M., & Nelson, C. A. (2015). Visual evoked potentials detect cortical processing 33 34 deficits in Rett syndrome. Annals of Neurology, 78(5), 775-786. https://doi.org/10.1002/ana.24513 35 LeBlanc, J. J., & Nelson, C. A. (2016). Deletion and duplication of 16p11.2 are associated with 36 opposing effects on visual evoked potential amplitude. Molecular Autism, 7(1), 30. 37 https://doi.org/10.1186/s13229-016-0095-7 38 Lozano, R., Hare, E. B., & Hagerman, R. J. (2014). Modulation of the GABAergic pathway for 39 the treatment of fragile X syndrome. Neuropsychiatric Disease and Treatment, 10, 1769-40 1779. https://doi.org/10.2147/NDT.S42919 41 42 Monachino, A. D., Lopez, K. L., Pierce, L. J., & Gabard-Durnam, L. J. (2021). The HAPPE plus Event-Related (HAPPE+ER) Software: A Standardized Processing Pipeline for Event-43

1	Related Potential Analyses. <i>BioRxiv</i> .
2	https://www.biorxiv.org/content/10.1101/2021.07.02.450946v1%0Ahttps://www.biorxiv.org/c
3	ontent/10.1101/2021.07.02.450946v1.abstract
4	Mullen, EM. (1995). Mullen Scales of Early Learning. American Guidance Service.
5 6	Odom, J. V., Bach, M., Barber, C., Brigell, M., Marmor, M. F., Tormene, A. P., & Holder, G. E. (2004). Visual evoked potentials standard (2004). <i>Documenta Ophthalmologica</i> , <i>108</i> (2),
7	115–123. https://doi.org/10.1023/B:DOOP.0000036790.67234.22
8	Qin, M., Huang, T., Kader, M., Krych, L., Xia, Z., Burlin, T., Zeidler, Z., Zhao, T., & Smith, C. B.
9 10	(2015). R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome. <i>International Journal of Neuropsychopharmacology</i> ,
11	18(9), pyv034. https://doi.org/10.1093/ijnp/pyv034
12	Van der Molen, M. J. W., Van der Molen, M. W., Ridderinkhof, K. R., Hamel, B. C. J., Curfs, L.
13	M. G., & Ramakers, G. J. A. (2012). Auditory and visual cortical activity during selective
14	attention in fragile X syndrome: A cascade of processing deficiencies. <i>Clinical</i>
15	Neurophysiology, 123(4), 720–729. https://doi.org/10.1016/j.clinph.2011.08.023
16	Varcin, K. J., Nelson, C. A., Ko, J., Sahin, M., Wu, J. Y., & Jeste, S. S. (2016). Visual evoked
17	potentials as a readout of cortical function in infants with tuberous sclerosis complex.
18	Journal of Child Neurology, 31(2), 195–202. https://doi.org/10.1177/0883073815587328
19	Wilkinson, C. L., & Nelson, C. A. (2021). Increased aperiodic gamma power in young boys with
20	Fragile X Syndrome is associated with better language ability. <i>Molecular Autism</i> , 12(1), 17.
21	https://doi.org/10.1186/s13229-021-00425-x
22	Zimmerman, I. L., Steiner, V. G., & Pond, R. E. (2011). <i>Preschool Language Scales, Fifth</i>
23	Edition (Fifth). Pearson Education, Inc.
24	http://www.pearsonclinical.com/language/products/100000233/preschool-language-scales-
25	fifth-edition-pls-5.html
26	
27	
28	
29 30	
30 31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	

- 1
- 2

3 List of Abbreviations

- 4 ADHD: Attention Deficit Hyperactivity Disorder
- 5 ADOS: Autism Diagnostic Observation Schedule
- 6 ANCOVA: Analysis of Covariance
- 7 ANOVA: Analysis of Variance
- 8 ASD: Autism Spectrum Disorder
- 9 EEG: Electroencephalogram
- 10 ERP: Event Related Potential
- 11 FDR: False Discovery Rate
- 12 FXS: Fragile X Syndrome
- 13 FMRP: Fragile X Messenger Ribonucleoprotein 1
- 14 GABA: Gamma-Aminobutyric Acid
- 15 HAPPE+ER: Harvard Automated Processing Pipeline for Electroencephalography plus Event-
- 16 Related Software
- 17 MSEL: Mullen Scales of Early Learning
- 18 NVDQ: Nonverbal Developmental Quotient
- 19 PLS: Preschool Language Scale
- 20 TSC: Tuberous Sclerosis Complex
- 21 VEP: Visual Evoked Potential
- 22
- 23
- 24
- 25
- 26
- 27 20
- 28
- 29 30
- 31
- 32
- 33
- 34
- 35
- 36 37

1 2	FIGURE TITLES AND LEGENDS
3	Figure 1: Grand average VEPs and P2 Amplitude across groups. (A) Grand-averaged VEPs
4	are shown, with 95% confidence intervals. (B) Mean P2 Amplitude across trials across groups.
5	P values shown are in comparison to the FXS group.
6	
7 8	Figure 2: VEP N1 Amplitude and fine motor development. Correlation between N1 Amplitude and MSEL fine motor raw score for FXS, Age Match, and Cognitive Match groups are
9 10	shown.
11	Figure 3: VEP component amplitudes and receptive language development. Correlation
12	between N1, P1, and P2 Amplitude and PLS Auditory Comprehension Raw score for FXS, Age
13	Match, and Cognitive Match groups are shown.
14	
15	
16	
17	
18	
19	
20	
21	
22	
23 24	
24 25	
23 26	
27	
28	
29	
30	
31	
32	
33	
34 25	
35	
36 37	
38	
39	
40	
41	
42	
43	
44	

1 DECLARATIONS

Acknowledgements: We thank all the families who participated in this study. We also thank
 Jack Keller, Megan Lauzé, and the Translational Neuroscience Center Human Neurobehavioral
 Core at Boston Children's Hospital for their assistance in data collection. We also thank the
 Infant Screening Study Team for their assistance in data collection of the cognitive-matched
 controls. We thank Graham Holt for his EEG technical support.

- Author Contributions: CLW contributed to the conception and design of the study. CLW, JF,
 and MH recruited participants and collected data. ES and CLW performed the data analysis and
 data visualization, and wrote the draft of the manuscript. All authors contributed to manuscript
 revision, read, and approved the submitted manuscript.
- 12
- 13 **Funding:** Support for this work was provided by: FRAXA Research Foundation, Autism Science
- 14 Foundation, The Pierce Family Fragile X Foundation, Thrasher Research Fund, Society for
- 15 Developmental Behavioral Pediatrics, Harvard Catalyst Medical Research Investigator Training
- 16 Award, the National Fragile X Foundation, and the National Institutes of Health
- 17 (1T32MH112510, 1K23DC017983-01A1, R01DC010290).
- Availability of data and materials: The datasets used and/or analyzed during the current study
 are available from the corresponding authors on reasonable request.
- 21

- Ethics approval and consent to participate: The study was approved by the institutional review board (#P00025493, P000183777).
- 24 Consent for publication: N/A
- 25
- 26 **Competing Interests:** The authors declare that they have no competing interests.
- 27
- 28 Author Information: Not applicable